KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) EBITDA (2016 - 2025)

Acadia Pharmaceuticals has reported EBITDA over the past 16 years, most recently at -$58.1 million for Q4 2025.

  • Quarterly results put EBITDA at -$58.1 million for Q4 2025, down 137.86% from a year ago — trailing twelve months through Dec 2025 was $29.3 million (down 87.3% YoY), and the annual figure for FY2025 was $29.3 million, down 87.3%.
  • EBITDA for Q4 2025 was -$58.1 million at Acadia Pharmaceuticals, down from $35.8 million in the prior quarter.
  • Over the last five years, EBITDA for ACAD hit a ceiling of $153.5 million in Q4 2024 and a floor of -$113.0 million in Q1 2022.
  • Median EBITDA over the past 5 years was $9.1 million (2023), compared with a mean of $5.3 million.
  • Biggest five-year swings in EBITDA: skyrocketed 902.21% in 2024 and later tumbled 137.86% in 2025.
  • Acadia Pharmaceuticals' EBITDA stood at $90.6 million in 2021, then soared by 46.47% to $132.7 million in 2022, then tumbled by 73.67% to $34.9 million in 2023, then surged by 339.28% to $153.5 million in 2024, then tumbled by 137.86% to -$58.1 million in 2025.
  • The last three reported values for EBITDA were -$58.1 million (Q4 2025), $35.8 million (Q3 2025), and $32.4 million (Q2 2025) per Business Quant data.